ORGANIZING COMMITTEE
Z. BASHIR
(UK)
G. BATTAGLIA
(ITALY)
M. BEAR
(USA)
D.V. BRUNO
(ITALY)
G. COLLINGRIDGE(UK)
P.J. CONN
(USA)
A. COPANI
(ITALY)
F. FERRAGUTI
(AUSTRIA)
P.J. FLOR
(SWITZERLAND)
F. GASPARINI
(SWITZERLAND)
R. GEREAU IV
(USA)
K. HUBER
(USA)
M. KANO
(JAPAN)
S. MACCARI
(FRANCE)
J. MONN
(USA)
R. NGOMBA
(ITALY)
R. NISTICÒ
(FRANCE)
J.P. PIN
(FRANCE)
T. SALT
(UK)
D.D. SCHOEPP
(USA)
M. WATANABE
(JAPAN)
M. ZHUO
(CANADA)
S. ZUKIN
(USA)
CONFERENCE CENTRE
Grande Albergo Capotaormina Via Nazionale, 105
98039 Taormina (Messina) Phone: +39.0942.57.21.11 Fax: +39.0942.62.54.67 web: www.capotaorminahotel.com
1
SCIENTIFIC SECRETARIAT
Ferdinando Nicoletti M.D.
Dept. of Human Physiology and Pharmacology
University of Rome “Sapienza”
Piazzale Aldo Moro, 5
00185 ROMA Italy
Phone: +39.06.49.91.29.69
Fax: +39.06.44.50.307 E-mail: [email protected]
[email protected]
ORGANIZING SECRETARIAT
CENTRO ORGANIZZAZIONE CONGRESSI Via Miss Mabel Hill, 9
98039 Taormina (ME) Italy
Phone: +39.0942.24293
Fax: +39.0942.24251
E-mail: [email protected]
Meeting web site: www.mglu.it
2
REGISTRATION INFORMATION
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
REGISTRATION FEES
Participants E 1.000,00
StudentsE
500,00 verification of student status required
Accompanying person
E
500,00
Registration fees includes:
Participants and students:
Access to all scientific sessions; congress kit; abstract book; welcome cocktail; coffee breaks; working lunches;
social program and local transportation.
AIRPORT SHUTTLE SERVICE
Free transportation from Capotaormina Hotel to Catania Airport will be
provided by the Organzing Committee
Friday 3nd and Saturday 4th October.
SCIENTIFIC INFORMATION
Oral communication
• Oral presentations must be prepared in
Power Point format (Windows system);
• Speakers are strongly recommended
to save their presentations on a pen
drive;
• Speakers with their presentations on
personal laptop are kindly requested
to go to the Multimedia Slide centre;
• We kindly recommend all speakers to
contact the Multimedia Slide centre
the day before their presentation.
Accompanying persons:
Welcome cocktail, working lunches, social program and local transportation.
The registration fee does not include the
insurance of participants against personal accidents, sickness, theft or property
damage.
All registered participants are anyhow
kindly requested to communicate departure details at the Registration Desk
within October 1st
Poster session
Poster session will take place on Tuesday
September 30th from 9.00 pm to 11.00
pm. in Alcantara room.
Poster can be positioned from 5.00pm to
9.00pm.
The presenters are required to be present
at their board during all time of the session.
The poster board will be 100 cm (39,4 inches) wide and 140cm (56,2 inches) high.
CONTINUING MEDICAL EDUCATION (Italian accreditation)
Request for ECM accreditation has
been submitted to the Ministry of Health for 1st, 2nd and 3rd October
Categories involved:
Neurology • Psychiatry • Clinical Biochemistry • Pharmacology and Toxico-
logy • Neurophisilogy • Neurophysiopathology
The Meeting has been accredited for
Italian CME: event n. 99799 (11,5 credits) - for Italian participants only.
3
SOCIAL PROGRAM
Sunday, September 28th
Grande Albergo Capotaormina Welcome Cocktail
Monday, September 29th
Taormina Hotel Timeo
Cocktail buffet
Via Teatro Greco
Opera collection by
Greek Theatre in Taormina
Soprano Dimitra Theodossiou
accompanied by Maestro Giacomo Scinardo
Violinist Giovanni Zanon and Beatrice Zanon
accompanied by Maestro Pierluigi Piran
Tuesday, September 30th
Grande Albergo Capotaormina Standing buffet
Alcantara room
Wednesday, October 1st
Grande Albergo Capotaormina Beach party
Thursday, October 2nd
Taormina’s Garden
Via Bagnoli Croce
Sicilian buffet with music with:
Leonardo Marino, Emiliana Perina
and Lia Fiducia
4
SCIENTIFIC PROGRAM
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
Sunday, September 28th
4.20-4.30 p.m.Welcome
OPENING SYMPOSIUM P.M.
Chair: J. P. Pin (France) and D.D. Schoepp (USA)
4.30-4.55
4.55-5.20
Structure and function studies of the mGlu5 receptor in the
design of novel negative allosteric modulators
K.A. Bennett, A.S. Doré, K. Okrasa, J.C. Patel, M. Serrano-Vega,
R. M. Cooke, J. C. Errey, A. Jazayeri, B. Tehan, G.R. Wiggin,
J.A. Christopher and F.H. Marshall (UK)
Cryo-EM visualization of a metabotropic glutamate receptor
G. Skiniotis (USA)
5.20-5.45
Time-Resolved Fluorescent Sensors as powerful High Throughput
Screening tools for Metabotropic Glutamate Receptors
E. Trinquet (France)
5.45-6.10
Functional organization and dynamics of mGluR transmembrane domains
6.10-6.35
6.35- 7.00
P. Rondard (France)
Optical analysis of receptor activation and signaling
M.J. Lohse (Germany)
Optical dissection of mGluR function
E. Isacoff (France)
7.00-7.25
Optical Control of metabotropic glutamate receptor with
photoswitchable drugs
A. Llebaria, S. Pittolo, X. Gómez-Santacana, K. Eckelt, X. Rovira,
J. Dalton, C. Goudet, J.-P. Pin, A. Llobet, J. Giraldo and P. Gorostiza
(Spain and France)
7.25-7.50
Fine tuning of sub-millisecond conformational dynamics
controls mGluR agonist efficacy
J.P. Pin, L. Olofsson, S. Felekyan, E. Doumazane, P. Scholler, L. Fabre,
J.M. Zwier, P. Rondard, C.A.M. Seide and E. Margeat (France and Germany)
Welcome cocktail at Grand Hotel Capotaormina
5
Monday, September 29th
Morning session 8.00 a.m.
MOLECULAR AND FUNCTIONAL CHARACTERIZATION
Chair: J. Bockaert (France) and P. Worley (USA)
8.00 -8.25
A genetic dissection of synaptic glutamate receptor function
R. Nicoll (USA)
8.25-8.50
Gating of the orphan GluD2 receptor by the mGlu1 receptor
8.50-9.15
P. Worley (USA)
9.15-9.40
Regulation of Metabotropic Glutamate Receptor function by
interacting proteins.
L. Fagni (France)
A role for Pin1 prolyl isomerase in group 1 mGluR signaling
A. Francesconi (USA)
9.40-10.05
Surprising Consequences of metabotropic glutamate receptor
heteromerization
P.J. Kammermaier (USA)
10.05-10.30
Coffee break
10.30-10.55
Molecular Mechanisms Regulating Group I Metabotropic
Glutamate Receptors
10.55-11.20
Presynaptic release-regulating mGlu receptors: un update
A. Pittaluga (Italy)
11.20-11.45
mGluR1 modulates the production of exosomes in melanoma cells
11.45-12.10
Signal transduction of mGlu1 receptors in neurons and cancer cells
J.T. Wroblewski (USA)
Working lunch
6
K. Roche (USA)
S. Chen, A. L. Isola, Y. Wen and J. Goydos (USA)
Monday, September 29th
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
Afternoon session 3.00 p.m.
Functional Anatomy
Chair: F. Ferraguti (Austria) and R. Shigemoto (Austria)
3.15-3.40
The synaptic targeting of mGluR1 by its carboxyl-terminal
domain is crucial for cerebellar function
A. Aiba (Japan)
3.40-4.05
Distinct mechanisms of short- and long-term motor learning
in the cerebellum
R. Shigemoto (Austria)
4.05-4.30
Synapse-specific molecular imaging at the nanoscale in intact
brain circuits
I. Katona (Hungary)
4.30-4.55
Role of Metabotropic Glutamate receptor 2/3 in hippocampal
temporo-ammonic pathand cross talk with the Gabaergic and
Cholinergic systems
S. Gatti, T.M. Ballard, M. Lorez, M. Kessler, J. Messer, J. Wichmann,
J.G.Wettstein, B. Biemans, C. Risterucci and F. Knoflach (Switzerland)
4.55-5.15
Coffee break
5.15-5.40
Is there a Master Plan for the specific expression of group III
mGlu receptors in distinct presynaptic axon terminals?
F. Ferraguti (Austria)
5.40-6.05
Burst firing in the mediodorsal thalamus and related cognitive
circuits is modulated by metabotropic glutamate receptors
C.S. Copeland, S.A. Neale and T.E. Salt (UK)
7
Monday, September 29th
Afternoon session 6.05 p.m.
MGLU Receptors and Kynurenines
Chair: R. Schwarcz (USA) and V. Bruno (Italy)
6.05 -6.30
Kynurenine Pathway Metabolites as Modulators of
Glutamatergic Neurotransmission
R. Schwarcz, K.V. Sathyasaikumar, M. Tararina, H.-Q. Wu,
D.M. Bortz and J.P. Bruno (USA)
6.30-6.55
Reduced levels of xanthurenic acid in the blood of schizophrenic
patients
F. Fazio, L. Lionetto, M. Curto, F. Napolitano, G. Vignaroli, M. Capi,
V. Corigliano, A. Comparelli, L. Iacovelli, G. Mauro, V. Bruno,
G. Battaglia, P. Girardi, F. Nicoletti and M. Simmaco (Italy)
6.55-7.20
Cinnabarinic acid, an endogenous agonist of type-4
metabotropic glutamate receptor, suppresses experimental
autoimmune encephalomyelitis in mice
F. Fallarino, F. Fazio, C. Zappulla, S. Notartomaso, C. Busceti,
A. Bessede, P. Scarselli, C. Vacca, M. Gargaro, M. Allegrucci,
L. Lionetto, M. Simmaco, M. L. Belladonna and F. Nicoletti
(Italy and France)
Cocktail buffet in Taormina – Hotel Timeo
Performance at the Greek Theatre
Tuesday, September 30th
Morning session 8.15 a.m.
Drug Addiction
Chair: N. Cosford (USA) and P. Kalivas (USA)
8.15-8.40
R. Malenka, S. Lammel, E. Steinberg, N. Wall and K. Beier (USA)
8.40-9.05
Targeting mGluR1 to reverse cocaine-induced plasticity and
decrease craving
8
Neural mechanisms of reward and aversion
M.E. Wolf, J.A. Loweth, A.F. Scheyer and K.Y. Tseng (USA)
9.05-9.30
9.30-9.55
Development of a viral construct expressing a light-activated
mGluR5 receptor (OptoXR-mGluR5) for optogenetic applications
M. F. Olive, C. Ramakrishnan, L. Fenno and K. Deisseroth (USA)
mGlu5 receptors & extinction of drug-seeking
A. J. Lawrence (Australia)
9.55-10.15
Coffee break
10.15-10.40
Using Glial Release of Glutamate onto mGluRs to Control
Relapse to Drug Use
P. W. Kalivas, M.D. Scofield and C.D. Gipson (USA)
10.40-11.05
Design, Synthesis and Characterization of Small Molecule Group II
Metabotropic Glutamate Receptor Allosteric Modulators
11.05-11.30
Presynaptic mGluR2 and mGluR7 receptors critically modulate
psychostimulant dependence
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
N. Cosford (USA)
X. Li, A. Markou, A. Stoker, D.J. Sheffler, P.J. Conn and N.D.P. Cosford (USA)
11.30-11.55
Mechanisms Underlying the mGluR2 Autoreceptor Function
and its Role in Control of Alcohol Drinking
Working lunch
D.M. Lovinger, Z. Zhou, M. Heilig and D. Goldman (USA)
Tuesday, September 30th
Afternoon session 3.00 p.m.
Development plasticity and disorder
of synaptic function
Chair: M. Kano (Japan) and M. Watanabe (Japan)
3.00-3.25
3.25-3.50
Requirement of mGluR1 for experience-dependent remodeling
of mouse retinogeniculate synapses
M. Kano, M. Narushima, M. Uchigashima, M. Watanabe, A. Aiba
and M. Miyata (Japan)
mGluR1 sculpts heterologous inputs to cerebellar Purkinje cells
M. Watanabe and R. Ichikawa (Japan)
9
3.50-4.15
mGlu1 Receptors epigenetically suppresse mGlu5 Receptors
in the cerebellum
S. Notartomaso, C. Zappulla, G. Mascio, M. Motolese, M. Cannella,
P. Scarselli, R. Gradini, G. Battaglia, V. Bruno and F. Nicoletti (Italy)
4.15-4.40
Coordination between translation and degradation regulates
inducibility of mGluR-LTD
P. E. Castillo, M. E. Klein and B. A. Jordan (USA)
4.40-5.05
Role of Metabotropic and Ionotropic Glutamate Receptor
signaling in activity-dependent spine shrinkage
K. Zito, W.C .Oh, I.S. Stein, L.K. Parajuli and T.C. Hill (USA)
5.05-5.25
Coffee break
Tuesday, September 30th
Afternoon session 5.25 p.m.
Synaptic plasticity and cognitive FUNCTIONS
Chair: G. Collingridge (UK) and Z. Bashir (UK)
5.25-5.50
5.50-6.15
Visualization of AMPA Receptor Synaptic Plasticity In Vivo
R. L. Huganir (USA)
mGlu2 receptors: are they needed?
D. Lodge, M. Byrne, L. Ceolin, S.L. Choi, B. Conway-Campbell,
M. Mercier, C. Nicolas, E. Robinson and C. Wood (UK)
6.15-6.40
GluA2 and actin regulation of mGluR-dependent long-term
depression in the hippocampus
Z. Jia (Canada)
6.40-7.05
Involvement of mGlu5 in synaptic information processing in the
CA3 region in vivo: the key to pattern completion?
D. Manahan-Vaughan and H. Hagena (Germany)
7.05-7.30
mGlu1 receptor-induced LTD of NMDA receptor transmission
selectively at Schaffer collateral-CA1 synapses mediates
metaplasticity
10
Z.I. Bashir, M. Bhouri, P. A. Farrow, A. Motee, X. Yan, G. Battaglia,
L. Di Menna, B. Riozzi, F. Nicoletti and S. M. Fitzjohn (UK and Italy)
7.30-7.55
Disrupted cross-laminar cortical processing in β-amyloid
pathology precedes cell death
K. G. Reymann (Germany)
7.55-8.20
mGluR5 and Amyloid-beta mediated aberrant synaptic
plasticity and object cognition deficit
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
K. Cho (UK)
8.20-8.45
mGluR2 Negative Allosteric Modulators compare favorably to
standard of care with respect to pro-cognitive effects in rhesus
monkey
J. M. Uslaner (USA)
Tuesday, September 30th
Evening session
9.00 p.m.
Poster Session - Alcantara Room
Dinner buffet at Grande Albergo Capotaormina
Wednesday, October 1st
Morning session 7.45 a.m.
mGlu and depression/anxiety
Chair: S. Chaki (Japan) and A. Pilc (Poland)
7.45-8.10
Potential of mGlu2/3 receptor antagonists for treatmentresistant depression: comparison with ketamine
S. Chaki (Japan)
8.10-8.35
Efficacy and Safety of a Novel mGlu2 Receptor Positive
Allosteric Modulator as an Adjunctive Treatment to an SSRI/
SNRI in the Treatment of Anxious Depression
J.M. Kent, E. Daly, M. Ceusters, I. Kezic, R. Lane, P. Lim, H. De Smedt,
P. De Boer, L. Van Nueten, and W. Drevets (USA and Belgium)
8.35-9.00
Acetyl-L-carnitine as a novel proneurogenic and antidepressant
drug: contribution of mGlu2 receptors
M. Grilli, B. Cuccurazzu, V. Bortolotto, M.M. Valente, A. Koverech
and P.L. Canonico (Italy)
11
9.00-9.25
Targeting the epigenetic control of mGlu2 to reverse the
stress-induced loss of resilience: implications for
next-generation psychiatric treatments
C. Nasca, B. Bigio, D.Zelli and B.S. McEwen (USA)
9.25-9.50
The opposing efficacy of mGlu receptor agonists and antagonist
in depression vs. schizophrenia A. Pilc, A. Pałucha-Poniewiera and J.M. Wierońska (Poland)
9.50-10.10
10.10-10.35
Coffee break
Potential utility of full and partial mGlu5 NAMs in major
depression and addictive disorders
J. Rook (USA)
10.35-11.00
Discovery of the mGlu5 negative allosteric modulator
basimglurant (RO4917523)
G. Jaeschke, S. Kolczewski, E. Vieira, B. Büttelmann, J. Huwyler,
J.U. Peters, E. Prinssen, A. Ricci, D. Rueher, M. Schneider, P. Spurr,
D. Tännler, J. Wichmann, J.G. Wettstein, R. Porter, W. Spooren
and L. Lindemann (Switzerland)
Wednesday, October 1st
Morning session 11.00 a.m.
Pain
Chair: M. Zhuo (Canada) and V. Neugebauer (USA)
11.00-11.25
12
Pain-related mGluR modulation of medial prefrontal
cortex-amygdala interactions
V. Neugebauer, G. Ji and T. Kiritoshi (USA)
11.25-11.50
Metabotropic glutamate receptor (mGluR) dependent synaptic
plasticity in pain-related cortex and their roles in chronic pain
M. Zhuo (Canada)
11.50-12.15
Broad spectrum efficacy with LY2969822, a metabotropic
glutamate 2/3 agonist prodrug of LY2934747, in rodent
pre-clinical pain models.
M.P. Johnson, M.A. Muhlhauser, E. Nisenbaum, R.M.A. Simmons,
B. Forster, K.L. Knopp, L. Yang, D. Morrow, D.L. Li, J.D. Kennedy
and J.A. Monn (USA)
12.15-12.40
Fenobam: a clinical tool compound for assessment of the role
of mGlu5 in human pain processing
12.40-13.05
N-acylethanolamines modulate glutamate transmission in the
prelimbic cortex of neuropathic mouse
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
L. F. Cavallone, M.C. Montana, K. Frey, M. Wages, K. Regina
and R.W. Gereau IV (USA)
S. Maione, L. Luongo, R. Romano, F. Guida, S. Boccella, F. Napolitano,
V. de Novellis and A. Usiello (Italy)
Working lunch
Wednesday, October 1st
Afternoon session 3.00 p.m.
Pharmacology and drug development
Chair: J. Monn (USA) and F. Acher (France)
3.00-3.20
LY2491503, A Novel mGluR1 Antagonist for Persistent Pain:
From Clone to Clinic
E.S. Nisenbaum, S. Iyengar, K.L. Knopp, R.M. Simmons, D. Li,
M.J. Fisher, S. Kuklish, V.N. Barth, M.G. Chambers, B.A. Heinz,
S.A. Monk, P. Zanotti-Fregonara, J-S Liow, R. Xu, V.W. Pike,
R.B. Innis and L.A. Arendt-Nielsen (Denmark and USA)
3.20-3.40
LY2934747: In Vitro and In Vivo Characterization of a Novel
mGlu2/3 Receptor Agonist
3.40-4.00
Discovery and early clinical evaluation of a novel mGlu2
Receptor Positive Allosteric Modulator
D. McKinzie, B. Heinz, X. Wang, D. Schober, C. Felder, H. Sanger,
R. Vivier, E. Siuda, E. Nisenbaum, L. Thompson, B. Johnson,
K. Knitowski, D. Shaw, L. Rorick-Kehn, J. Katner, K. Perry, M. Johnson,
C. Beadle, S. Atwell, F. Lu, D. Clawson, M. Bures, S. Swanson
and J. Monn (USA and UK)
P. De Boer, H. Lavreysen, I. Kezic, M. Ceusters, H.De Smedt,
L. Van Nueten, W. Drevets and J.M. Kent (Belgium and USA)
4.00-4.20
Discovery of LY3020371, a potent and selective mGlu2/3
receptor antagonist, for the treatment of depression
J.M. Witkin and J.A. Monn (USA)
13
4.20-4.40
Discovery of novel mGlu3-selective allosteric modulators
provides new insights into mGlu3 function
C. Wenthur (USA)
4.40-5.00
Coffee break
5.00-5.20
New orthosteric group-III mGluR ligands
F.C. Acher, B. Commare, I. Brabet, D. Rigault, H.O. Bertrand,
C. Goudet and J.-P. Pin (France)
5.20-5.40
Supra-Physiological Pharmacology by mGlu4 Receptor Positive
Allosteric Modulators
X. Huang, M. D. Collins, N. J. Boyle, H. Zhang, E. Dale, M. Jørgensen,
C. Bundgaard, L. K. Isaac, M. H. Schmidt, H. Zhong, F. C. Acher,
R. M. Brodbeck and D. Doller (USA, Denmark and France)
5.40-6.00
The Discovery and Preclinical Characterization of the Novel
mGluR5 Negative Allosteric Modulator PF470: Implications for
Mechanism-based Toxicity?
C. L. Shaffer (USA)
6.00-6.20
Progress Towards Novel Metabotropic Glutamate Receptor
4 (mGlu4) Positive Allosteric Modulators for CNS disorders
S. Célanire (Switzerland)
Wednesday, October 1st
Afternoon session 6.20 p.m. Regulation of thalamo-cortical network
Chair: J. Huguenard (USA) and R. Ngomba (Italy)
6.20-6.45
6.45-7.10
mGlu2 Receptors and sensory processing in the thalamus;
a tale of astrocytes and neurones
T.E. Salt, C.S Copeland, H. R. Parri, T. M. Wall, S.A. Neale and
E. Nisenbaum (UK and USA)
Role of thalamic mGluRs in EEG rhythms of wake and sleep
V. Crunelli (UK)
7.10-7.35
Modulation of Extrasynapitic GABAA Receptors by mGLU
Receptors
14
G. Di Giovanni, V. Crunelli and A. C. Errington (Malta and UK)
7.35-8.00
8.00-8.25
Group III metabootropic receptors modulate synaptic plasticity
in the corticothalamic circuit
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
J. Huguenard and C. Kyuyoung (USA)
Is there a future for Group I PAMs in epilepsy?
G. Van Luijtelaar and R. Ngomba (The Netherlands and Italy)
Beach party at Grande Albergo Capotaormina
Thursday, October 2nd
Morning session 7.45 a.m.
Schizophrenia
Chair: P.J.Conn (USA) and F. Matrisciano (USA)
7.45 -8.10
Targeting glutamate neurotransmission for prevention of psychosis
8.10-8.35
Allosteric modulator effects and physiological roles of mGlu receptor
heterodimers in identified brain circuits
8.35-9.00
DNA methylation and hydroxymethylation in psychiatric disease.
9.00-9.25
Structural insights into the crosstalk mechanism between 5-HT2A
and mGlu2 receptors in schizophrenia
9.25-9.50
Functional brain imaging of experimental Group II metabotropic
glutamate receptor (mGluR) agonists LY2979165 and LY2140023
in healthy human subjects
9.50-10.10
Coffee break
B. Moghaddam (USA)
P. J. Conn, A. Ghoshal, X. Xiang, J.M. Rook, C.W. Lindsley, S. Yen,
C.K. Jones and C.M. Niswender (USA)
D.R. Grayson and A. Guidotti (USA)
J. González Maeso (USA)
A. J. Schwarz, A. Schmechtig, J. McColm, K. Jackson, C. Brittain,
C. Gonzales, S. Suriyapperuma, J. Foster, S. Tauscher-Wisniewski,
B. Kinon and M.A. Mehta (USA)
15
10.10-10.35
The development of pomaglumetad methionil as a glutamate-based
pharmacotherapy for schizophrenia: lessons learned
10.35-11.00
Glutamate Receptors genes and schizophrenia
V. L. Stauffer (USA)
M. Gennarelli and E. Sacchetti (Italy)
Thursday, October 2nd
Morning session 11.00 a.m.
Neurodevelopment / Autism
Chair: W. Spooren (Switzerland) and B.K. Kaang (Korea)
11.00-11.25
EU-AIMS: mGlu1 from mouse to patient
D. Murphy (UK)
11.25-11.50
11.50-12.15
12.15-12.40
mGluR5 as a Fragile X Treatment Target
M.R. Tranfaglia (USA)
mGluR4 and psychiatric disorders
B. Biemans and G. Jaeschke (Switzerland)
Glutamate receptors and autism
B.K. Kaang (Korea)
Working lunch
Thursday, October 2nd
Afternoon session 2.45 p.m.
Autism
Chair: K.M. Huber (USA) and M.V. Catania (Italy)
2.45-3.10
Targeting MAP-kinase interacting kinases restores protein synthesis
homeostasis and improves behavioral deficits in neuroligin-3 mouse
model of autism
3.10-3.35
Regulation of mGluR5-Homer scaffolds in Fragile X Syndrome mice
16
S. Baudouin, L. Burkle and P. Scheiffele (Switzerland and UK)
K.M. Huber, W. Guo, K.A. Collins, G. Molinaro and P. F. Worley (USA)
3.35-4.00
4.00-4.25
4.25-4.50
Taormina,
Sicily-Italy
September 28th
October 3rd,
Dysfunctions of metabotropic glutamate receptor subtype 5 (mGlu5) 2014
receptors in a mouse model of Fragile X syndrome
M.V. Catania, M. Spatuzza, E. Aloisi, S. D’Antoni, J.P. Dupuis, L. Costa,
C. M. Bonaccorso, G. Molinaro, G. Battaglia, S. Musumeci, L. Davidovic,
B. Bardoni, L.Ciranna, F. Nicoletti, L. Groc and A. Frick (Italy and France)
Activity-dependent Arc expression: mechanism, function
and application
H. Bito (Japan)
Synaptopathies of the mGlu signalosome
O.J. Manzoni, H.G.S. Martin, A. Bilbao, D. Neuhofer, O. Lassalle,
A. Thomazeau and R. Spanagel (France and Germany)
4.50-5.05
Coffee break
5.05-5.30
Mutations of the SHANK genes and alterations of mGlu5 signaling
5.30-5.55
Aberrant cofilin signaling in a mouse model of Fragile X syndrome
5.55-6.20
Synaptic and Circuit Mechanisms for Striatal mGluR5 Signaling in
Compulsive Behaviors
6.20-6.45
Metabotropic glutamate receptor 7: a novel target for the
treatment of Rett Syndrome
C. Sala, C. Verpelli, C. Vicidomini and D.I. Orellana (Italy)
S. Zukin (USA)
N. Calakos (USA)
C. M. Niswender, R. Klar, R.G. Gogliotti, R. Zamorano, A.G. Walker,
Z. Xiang and P.J. Conn (USA)
6.45-7.10
Structural Plasticity of Dendritic Spines During Long-Term
Depression
M. Bosch and M. Bear (USA)
7.10-7.35
Facilitating glutamate mGluR4 receptor signaling relieves
autistic-like deficits in mice
Dinner at Taormina’s Garden
Sicilian buffet with music
J. Le Merrer, J.A.J. Becker and B.L. Kieffer (France and Canada)
17
Friday, October 3rd
Morning session 7.45 a.m.
Emerging roles for mGlu7 and mGlu8 receptors as
drug targets in neural and somatic disorders
Chair: P.J. Flor (Germany) and J.F. Cryan (Ireland)
7.45-8.10
Therapeutic Potential of Orthosteric and Allosteric mGlu7
Receptor Drugs
8.10-8.35
mGlu7: A therapeutic target for stress-related disorders of brain
and gut
8.35-9.00
mGlu7 Receptor Modulation Relieves Behavioral and Physiological
Consequences Induced by Chronic Psychosocial Stress
9.00-9.25
The last mGlu: Is mGlu8 a therapeutic target?
9.25-9.50
Role of mGlu7 and mGlu8 receptors in event learning
9.50-10.10
Coffee break
P. J. Flor, C.E. Gee, D. Peterlik, N. Uschold-Schmidt, J. F. Cryan,
R. Bouhelal, M. Fendt, F. Gasparini, I. Vranesic, R. Glatthar
and H. van der Putten (Germany and Ireland)
J.F. Cryan (Ireland)
N. Uschold-Schmidt, D. Peterlik, A. Bludau, T. Killian, D. Grabski,
S. O. Reber and P. J. Flor (Germany)
R.M. Duvoisin and J. Raber (USA)
M. Fendt (Germany)
Friday, October 3rd
Morning session 10.10 a.m.
Exitotoxcity, Brain Ischemia ad Parkinson's disease
Chair: G. Battaglia (Italy) and A. Copani (Italy)
10.10-10.35
18
Group I metabotropic glutamate receptors mediate
inflammation-induced sensitization to excitotoxic neurodegeneration
P. Gressens (France)
10.35-11.00
mGluRs in stroke
11.00-11.25
Role of ionotropic and metabotropic glutamate receptors in models
of ischemic tolerance
11.25-11.50
MGluR5 Antagonists and neuroprotection in Parkinson’s disease:
An effect that extends beyond dopaminergic cell groups
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
T. Wieloch (Sweden)
D.E. Pellegrini-Giampietro, E. Gerace, E. Zianni, F. Gardoni,
T. Scartabelli, E. Landucci, F. Moroni, G. Mannaioni and M. Di Luca (Italy)
Y. Smith (USA)
11.50-12.15 Targeting metabotropic glutamate receptors (mGluRs) in Parkinson’s
disease
M. Amalric (France)
12.15-12.40
Preclinical and clinical evaluation of dipraglurant, a novel negative
allosteric modulator (NAM) of the mGlu5 receptor for the treatment
of dystonia and levodopa induced dyskinesia
S. Poli (Switzerland)
12.40-1.05pm mGlu5 receptors in Parkinson’s disease and MPTP-lesioned
monkeys: behavior and brain molecular correlates
T. Di Paolo, N. Morin, B. Ouattara, L. Grégoire , M. Morissette,
P. Samadi, F. Gasparini, A. Rajput , A. H. Rajput and B. Gomez-Mancilla
(Canada and Switzerland)
1.05-1.30pm Antagonism of mGluR5 to treat L-DOPA-induced dyskinesia:
when and how would this treatment work?
M.A. Cenci (Sweden)
1.05-1.30pm mGluR3 PAM as novel neuroprotective therapeutic strategy
for Parkinson’s Disease
S. Schann (France)
Working lunch
19
POSTER SESSION
Tuesday, September 30th
evening session: 9.00 pm.00 -11.00 p.m.
Alcantara Room - Hotel Capotaormina
The poster board will be 100 cm (39,4 inches) wide and 140 cm (56,2 inches) high
Receptor localization and function
1. Towards functional and pharmacological characterization of mGlu
heterodimers
D.Moreno, P. Scholler, E. Doumazane, P. Rondard and J.P. Pin (France)
2. Heterodimerization between dopamine D1 and Glutamate mGlu5
receptors controls cellular signaling
E. Goyet, N. Bouquier, V. Homburger, A. Burguière, L. Fagni and J. Perroy (France)
3. Molecular mechanisms that desensitize Metabotropic Glutamate
Receptors: an overview
L. Iacovelli, F. Nicoletti and A. De Blasi (Italy)
4. Investigating the molecular mechanisms underlying the differential
subcellular targeting of the metabotropic glutamate receptor 1 (mGlu1) in
the cerebellar cortex
M. Mansouri, H. Lindner and F. Ferraguti (Austria)
5. Altered proteomic profile in synaptic endings from brain cortex of
Grm1crv4 mice
I. Musante, L. Musante, M. Bruschi, P.I. Rossi, L. Emionite, G. Candiano, R.
Ravazzolo, A. Pittaluga and A. Puliti (Italy)
6. Extracellular Chloride Modulates Metabotropic Glutamate Receptors
Activity
A.Tora, X. Rovira, N. Doyon, H.O. Bertrand, I. Brabet, Y. De Koninck, J.P. Pin, F.
Acher and C. Goudet (France and Canada)
7. Structural Basis of Chloride Selectivity between Group II Metabotropic
Glutamate Receptors
20
E.J. Miller, J.O. DiRaddo, E. Grajkowska, B. Wroblewska, B.B. Wolfe, J.P. Snyder,
J.T. Wroblewski and D.C. Liotta (USA)
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
8. Chloride is an Agonist of mGlu3, mGlu4, mGlu6, and mGlu8 Receptors
J.O. DiRaddo, E.J. Miller, E. Grajkowska, B. Wroblewska, J.P. Snyder, B.B. Wolfe,
D.C. Liotta and J.T. Wroblewski (USA)
9.
A Real-Time Method for Measuring cAMP Production Modulated by Gαi/
o-Coupled Metabotropic Glutamate Receptors
J.O. DiRaddo, E.J. Miller, H.A. Hathaway, E. Grajkowska, B. Wroblewska; B.B.
Wolfe; D.C. Liotta and J.T. Wroblewski (USA)
10. The contribution of high glutamate concentration on mGlu 7 receptors
functionality in cAMP accumulation assays
G. Burnat, P. Brański, B. Chruścicka , M. Marciniak and A. Pilc (Poland)
11. The group II metabotropic glutamate receptor mGlu3 poteniates cAMP
production and reduces excitatory transmission in a form of glial-neuronal
communication induced during coincident β-adrenergic receptor
activation.
D.J. Sheffler, A.G. Walker, A.S. Lewis, Z. Xiang and P.J. Conn (USA)
12.Tetracycline-based system for controlled inducible expression of
metabotropic glutamate receptors.
B. Chruścicka, G. Burnat, P. Brański and A. Pilc (Poland)
13.Modulation of hippocampal synaptic transmission and functional
evaluation of the kynurenine pathway member xanthurenic acid
C.S. Copeland, S.A. Neale and T.E. Salt (UK)
14. GLYT1, NMDA and AMPA autoreceptors in hippocampal glutamatergic
nerve endings: an unexpected “ménage a trois”
E. Merega, S. Prisco Silvia, D. Graglia, S. Righetti and A. Pittaluga (Italy)
15. Presynaptic release regulating mGlu2/3 autoreceptors in mouse cortex
and spinal cord.
S. Di Prisco, E. Merega , D. Graglia , S. Righetti and A. Pittaluga (Italy)
Drug development
16.Metabotropic Glutamate
Computational Modeling
Receptors:
A
Challenging
System
I. Lans, J. Dalton, X. Rovira, D. Roche, C. Christov and J. Giraldo (Spain)
for
21
17. Characterization of the mGlu2 PAM radioligand[3H]JNJ-46281222and its
application for ex vivo receptor occupancy in rat brain.
P.te Riele, I. Biesmans, L. Peeters, H. Lavreysen and X. Langlois (Belgium)
18. Development of novel mGlu1 PAMs as tools to improve functionality of
mutant receptor isoforms found in a schizophrenic population.
P. M. Garcia-Barrantes, H. P. Cho, J. T. Brogan, C.R. Hopkins, C. M. Niswender, R.
D. Morrison, J. S. Daniels, P. J. Conn and C. W. Lindsley (USA)
19.Synthesis and characterization of pyrazolo[1,5-a]quinazolin-5-one
derivatives: potent non-competitive mGluR2 NAMs. From hit toin vivo
procognitionProof of Concept.
S. Mayer, C. Amalric, L. Cardona, T. Catelain, F. Courivaud, G. Hommet, N. Lotz,
B. Manteau, S. Mikidadi, E. Steinberg, L. Deshons, L. Baron, S. Scheffler, C.
Franchet, M. Frauli and S. Schann (France)
20. Structural aspects of agonist and antagonist binding to human mGlu2
and mGlu3 receptors amino terminal domains
J. Hao, S. Ashok, S. Atwell, K. Bain, M. Bures, J. H. Carter, D. Clawson, B. Condon,
K. Conners, M. Dickey, T. Gheyi, C. Groshong, B. Heinz, F. Lu, M. Kearins, R.
Madsen, D. Manglicmot, L. Rodgers, M. Rutter, M. Vargas, J. Wang, X. Wang, A.
Zhang and J. A. Monn (USA)
21. LY2969822: Pharmacological characterization of an orally bioavailable
prodrug for a potent, selective mGlu2/3 receptor agonist
D. McKinzie, B. Johnson, K. Knitowski, D. Shaw, L. Rorick-Kehn, J. Katner, K.
Perry, S. Swanson, J. Catlow, M. Johnson, L. Prieto, C. Beadle and J. Monn (USA
and Spain)
22.Synthesis and characterization of thioheteroaryl-substituted bicyclic
amino acids. Identification of potent, functionally selective mGlu2receptor agonists
J. A. Monn, L. Prieto, L. Taboada, J. Hao, M.R. Reinhard, S. S. Henry, C. Beadle, L.
Walton, T. Man, H. Rudyk, B. Clark, D. Tupper, S. R. Baker, C. Lamas, C. Montero,
A. Marcos, J. Blanco, M. Bures, D.K. Clawson, S. Atwell, F. Lu, M. Russell, B.
Heinz, X. Wang, J. Carter, B. Getman, J. Catlow, S. Swanson, B. G. Johnson, D.
Shaw and D. L. McKinzie (USA)
23. In vitro attributes of LY3020371, a potent and selective mGlu2/3 receptor
antagonist
22
J. A. Monn, J. M. Witkin, P. L. Ornstein, C. H. Mitch, R. Li, S. C. Smith, X. Wang, C.
Xiang, J. H. Carter, J. Wang, S. Atwell, F. Pasqui, S. Fitzjohn and B. A. Heinz (USA
and UK)
Taormina,
Sicily-Italy
September 28th
October 3rd,
24. LY3020371: In vivo characterization of a novel mGlu2/3 receptor 2014
antagonist
J.M. Witkin, C. Overshiner, X. Li, G. Gilmour, J. Li, L. Rorick-Kehn, K. Rasmussen,
B. Johnson, SN Mitchell, K.G. Phillips, K.A. Wafford, D.L. McKinzie, A. Nikolayev,
V.V. Tolstikov, M-S Kuo, P.L.Ornstein, C.H.Mitch, R. Li, S.C. Smith, X-S Wang, B.A.
Heinz, D. Allen, S. Swanson and J.A. Monn (USA and UK)
25.Safety, Tolerability, and Pharmacokinetic Evaluation of Single- and
Multiple- Doses of LY2979165, a Pro-drug of an Orthosteric metabotropic
Glutamate 2 (mGlu2) Receptor Agonist in Healthy Subjects
J. McColm, S. Swanson, S. Tauscher-Wisniewski, J. Foster, S. Suriyapperuma and
K. Jackson (USA)
26. The selective mGlu4 receptor agonist LSP1-2111 is not transformed into
L-AP4 under alkaline pH conditions
H. Pedersen, X. Huang, F. Acher and D.Doller (Denmark, USA and France)
27.Positive allosteric modulation of mGlu4 receptors: challenges and
opportunities
E. Dale, H. Hong, X. Huang, N. J. Boyle, M. Collins, J.A.Tamm, R.M. Brodbeck, H.
Zhong, F. Acher and D. Doller (USA and France)
28.Overlapping binding sites drive allosteric agonism and positive
cooperativity in type 4 metabotropic glutamate receptors
X. Rovira, F. Malhaire, P. Scholler, J. Rodrigo de Losada, P. Gonzalez-Bulnes, A.
Llebaria, J.P. Pin, J. Giraldo and C. Goudet (France and Spain)
29. Clickable photoaffinity labels for metabotropic glutamate receptor 5
based on allosteric modulator scaffolds
K. J. Gregory, R. Velagaleti, D.M. Thal, A. Christopoulos, P. J. Conn and D.J.
Lapinsky (Australia and USA)
30. Licencing opportunity for RGH-618 an orally active mGluR5 negative
allosteric modulator
K. Gál, M. Darida, M. Kapás, Gy. Selényi and S. Farkas (Hungary)
31. Preclinical pharmacological profile of basimglurant (RO4917523,
RG7090), a unique mGlu5 negative allosteric modulator in clinical
development for both Fragile X syndrome and depression
L. Lindemann, G. Jaeschke, R. Porter , S. Scharf, B. Kuennecke, M. von Kienlin, A.
Harrison, A. Paehler, C. Funk, A. Gloge, M. Schneider, N.J. Parrott, L. Polonchuk,
U. Niederhauser, S.R. Morairty, T.S. Kilduff, E. Vieira, B. Buettelmann, T. Hartung,
S. Kolczewski, M. Honer, E. Borroni, J.L. Moreau , E. Prinssen, W. Spooren and J.
G. Wettstein (Switzerland and USA)
23
32. IP27039 a novel nonselective mGluR8 agonist?
P. Brański, A. Hogendorf, G. Burnat, A. Bojarski, B. Chruścicka, R.Bugno and A.
Pilc (Poland)
33. (±)-AZ12216052 is not an optimal mGlu8 receptor positive allosteric
modulator tool compound
X. Huang, C.Bundgaard and D. Doller (USA and Denmark)
Sleep/Epilepsy
34. Metabotropic glutamate receptor type (mGlu7) action at GABAergic and
glutamatergic synapses of the mouse thalamocortical loop
V. Tassin, D. Rigault, M. Kalinichev, A. Chotte, B. Girard, F. Acher, L. Fagni and F.
Bertaso (France)
35. Effects of selective Group I Metabotropic Glutamate Receptor enhancers
locally infused in the cortico-thalamo-cortical circuit in the Wag/Rij rat
model of absence epilepsy
V. D’Amore, C. von Randow, T. van Rijn, I. Santolini, R. Celli, M. Guiducci, F.
Nicoletti, R. T. Ngomba and G. van Luijtelaar (The Netherland and Italy)
36. A role for group-I metabotropic glutamate receptors (mGluR1/5) in sleepwake regulation
A. Sousek, P. Franken, H-P. Landolt and M. Tafti (Switzerland)
37. FMR1 and mGluR5 as prospective molecular markers of sleep need in
humans
S.C. Holst, K. Hefti, A. Baumer, A. Buck, S.M. Ametamey, M. Scheidegger, R. Dürr,
E. Seifritz and H.-P. Landolt (Switzerland)
38.Ficus platyphylla ameliorates seizure severity and neuronal loss in
pentylenetetrazole-kindled mice – role of GABA-ergic and glutamatergic
systems
H. Schröder, B. A. Chindo and A. Becker (Germany and Nigeria)
Synaptic plasticity/ cognitive functions
39. The MK2/3 cascade regulates AMPAR trafficking and cognitive flexibility
24
K. L. Eales, O.Palygin, T. O’Loughlin, S. Rasooli-Nejad, M. Gaestel, J. Müller, D. R.
Collins, Y. Pankratov and S.A.L. Corrêa (UK and Germany)
40. Group I mGluR-dependent plasticity in hippocampal CA2
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
M. Samadi, S.M. Dudek and Z.I. Bashir (UK and USA)
41.Effects of mGluR2 Blockade on operant delayed non-matching to
position in rats
T. Steckler, N. Aerts, L. Ver Donck and J. Talpos (Belgium)
42. Procognitive effects of an mGlu2 negative allosteric modulatorin rats.
S. Embrechts, H. Van Craenendonck, D.J. Pemberton and L. Ver Donck (Belgium)
43. Allosteric modulators of metabotropic glutamate receptors as promising
therapeutic strategies for Alzheimer’s disease
J. M. Rook, J.W. Dickerson, A.Ghoshal, A.G. Walker, G.N. Roop, Q. Huan, S.R.
Stauffer, C. M. Niswender, J. S. Daniels, C. K. Jones, C.W. Lindsley and P.J. Conn
(USA)
44. Corticostriatal metaplasticity of group I metabotropic glutamate receptors
contributes to habit learning.
B. Greco, A. Cavaccini, A. Rocchi, M. Trusel, V. Paget-Blanc, M. Maria and R.Tonini
(Italy)
Peripheral organs
45.Possible functional expression of group III metabotropic glutamate
receptors in the male mouse reproductive system based on mGlu7
receptor example
M. Marciniak, B. Chruścicka, G.Burnat and A.Pilc (Poland)
46. Phenotypic characterization of Grm1crv4 mice reveals a functional role
for the type 1 metabotropic glutamate receptor in the skeleton
I. Musante, L. Otescu, G. Cangemi C. Gatti, D. Mattinzoli, R. Ravazzo, M.P.
Rastaldi, D. Riccardi and A. Puliti (Italy and UK)
47. Negative Allosteric Modulation of the mGlu7Receptor Reduces Visceral
Hypersensitivity in a Stress-Sensitive Rat Strain
R. D. Moloney, R. M O’Connor, M. Kalinichev, T. G. Dinan and J. F. Cryan (Ireland
and Switzerland)
25
Pain
48. LY2491503, A Novel mGluR1 Antagonist for Persistent Pain: From Clone
to Clinic
E.S.Nisenbaum, S. Iyengar, K.L. Knopp, R.M. Simmons, D. Li, M.J. Fisher, S.
Kuklish, V.N. Barth, M.G. Chambers, B.A. Heinz,S.A. Monk, P. Zanotti-Fregonara,
J-S Liow, R. Xu, V.W. Pike, R.B. Innis and L.A. Arendt-Nielsen (Denmark and USA)
49. The mGluR7 negative modulation alleviates pain and affective/cognitive
deficit in neuropathic mice.
E. Palazzo, R. Romano, S. Boccella, L. Luongo, F. Rossi and S. Maione (Italy)
50. Positive allosteric modulators (PAMS) of Metabotropic Glutamate Receptor
2 (mGluR2) are effective nerve injury induces facial allodynia in rats
Cs. Horváth, K. Galgóczy, K. Sz. Kordás, Á. Kis-Varga, Gy. Túrós, Gy. Szabó and
K. Gál (Hungary)
51. N-Acetyl-Cysteine, a drug that facilitates the endogenous activation
mGlu2/3 receptors, inhibits nociceptive transmission in humansa
A.Truini, S. Piroso, E. Pasquale, S. Notartomaso, G. Di Stefano, R.Lattanzi, F.
Nicoletti, G. Battaglia and G. Cruccu (Italy)
Autism
52.Acute biochemical and behavioural effects of indirect activation of
presynaptic inhibitory mGluR2/3 by N-acetylcysteine in the mouse.
A.Durieux, C. Fernandes, D.Murphy, M. Labouesse,S.Giovanoli, J. Horder, U.
Meyer, P. So and G. McAlonan (UK and Switzerland)
53. mGlu7 is Critical for Hippocampal Plasticity and is a Potential Therapeutic
Target for the Treatment of Rett Syndrome
R. Klar, R.G. Gogliotti, A.G. Walker, R. Zamorano, J.M. Rook, Z. Xiang, P.J. Conn
and C.M. Niswender (USA)
54. The development of mGlu5 positive allosteric modulators as Rettsyndrome
therapeutics
R. Gogliotti, R.Klar, A.Ghoshal, R.Zamorano, J.Rook,S. Stauffer, C. Lindsley,
P.J.Conn and C.M. Niswender (USA)
55. Altered mGlu5 receptor surface dynamics are linked to abnormal NMDA
receptor function and plasticity in Fragile X Syndrome
26
E. Aloisi, J.P. Dupuis, L. Costa, M.G. Haberl, M. Ginger, L. Ladépêche, F. Drago,
P.V. Piazza, L. Ciranna, L. Groc , M.V. Catania and A. Frick (Italy and France)
Taormina,
Sicily-Italy
September 28th
October 3rd,
56. Metabotropic glutamate subtype 5 (mGlu5) receptor-mediated modulation 2014
of the interaction between Fragile X Mental Retardation Protein (FMRP)
and the Fragile X related (FXR) proteins FXR1P and FXR2P.
C. M. Bonaccorso, S. D’Antoni, M. Spatuzza, B. Di Marco, G. Barrancotto, S.A.
Musumeci, L. Davidovic, B. Bardoni, M. V. Catania (Italy and France)
57.Selective disruption of mGluR5-homer interactions mimics multiple
phenotypes of fragile X syndrome in mice
G.Molinaro, K.A. Collins, W. Guo, C. M. Reyes, R. Paylor, K.K. Szumlinski, P.F.
Worley and K. M. Huber (USA)
58. Abnormalities in Subcortical Glutamate/Glutamine, But Not GABA, In
Adults With An ASD – A [1H]MRS Study
J. Horder, M. Mendez, N. Gillan, S. Coghlan and D. Murphy (UK)
59. A Visual Perceptual Task Provides Evidence for an Excitatory:Inhibitory
Imbalance in Adults with Autism
M. Mendez, J. Horder, D. Spain, J.Faulkner, J.D. De La Harpe Golden and D.
Murphy (UK)
Psychiatric disorders
60.Synthesis and Optimization of Small Molecule Negative Allosteric
Modulators (NAMs) of Group II Metabotropic Glutamate Receptors
(mGlus) for the Treatment of Mental Disorders
R.P. Dhanya, D.J. Sheffler, A. Herath, M. Davis, P.S. Lee, L. Yang, H.H. Nickols, H.P.
Cho, P.J. Conn, A. Der-Avakian, A. Markou and N.D.P. Cosford (USA)
61. The effect of mGlu4 selective agonist, LSP-42022 on the immobility time
in the TST and in the FST in mice.
A. Pałucha-Poniewiera, M. Marciniak, K. Podkowa, F. Acher and A. Pilc (Poland)
62. Blocking Metabotropic Glutamate Receptor Subtype 7 (mGlu7) via the
Venus Flytrap Domain (VFTD) Inhibits Amygdala Plasticity, Stress, and
Anxiety-related Behavior
D. Peterlik, C. E. Gee, C. Neuhäuser, R. Bouhelal, K. Kaupmann, G. Laue, N.
Uschold-Schmidt, D. Feuerbach, K. Zimmermann, S. Ofner, J. F. Cryan, H. van
der Putten, M. Fendt, I. Vranesic, R. Glatthar and P. J. Flor (Germany, Switzerland
and Ireland)
63.Modulation of mGlu7 Receptor Function Relieves Behavioral and
Physiological Consequences Induced by Chronic Psychosocial Stress
D. Peterlik, A. Bludau,T. Killian, D. Grabski, S. O. Reber, P. J. Flor and N. UscholdSchmidt (Germany)
27
64. Ketamine reduces evoked [3H]-D-aspartate release in the prefrontal
cortex of Flinders Sensitive Line rats
H.K. Müller, G. Treccani, K.G. du Jardin, G. Wegener and B. Elfving (Denmark)
65. Metabolomics Study of LY3020371, a potent and selective mGlu2/3
receptor antagonist, and Ketamine in Rats
M. Kuo, V. Tolstikov, A. Nikolayev, H. Wu, J.M. Witkin and J.A. Monn (USA)
66.The pharmacological studies of mGlu5-GABAB interplay in animal
models of psychosis.
JM. Wierońska, M. Woźniak, N. Kłeczek and A. Pilc (Poland)
67.Modulation of the rab GDP dissociation inhibitor (GDI) discloses a
pharmacodynamic difference between the mGlu2/3 receptor agonists,
LY379268 and LY354740.
R. Orlando, M. Borro, M. Motolese, G. Molinaro, S. Scaccianoce, A. Caruso,
L. di Nuzzo, F. Caraci, C. De Lucia, F. Matrisciano, A. Pittaluga, J. Mairesse, M.
Simmaco, R. Nisticò, J. A. Monn and F. Nicoletti (Italy and USA)
Addiction
68.Ethanol dependence and withdrawal in immature and mature rat
organotypic hippocampal slice cultures: different mechanisms mediated
by ionotropic and metabotropic glutamate receptors.
E. Gerace, E. Landucci, A. Totti, I. Orsini, V. Mazzucco, F. Moroni, G. Mannaioni
and D.E. Pellegrini-Giampietro(Italy)
69. Activation of Metabotropic Glutamate Receptor 7 attenuates nicotine
taking and nicotine seeking in rats
X. Li, A. Stoker and A. Markou (USA)
Neurodegenerative and neuroinflammatory
disorders
70. Activation of group-I metabotropic glutamate receptors impairs stress
granules formation and enhances cellular damage under stress condition.
28
B. Di Marco, P. Dell'Albani, M. Spatuzza, C. M. Bonaccorso, S. D'Antoni, B.
Bardoni, F. Drago, M.V. Catania (Italy and France)
Taormina,
Sicily-Italy
September 28th
October 3rd,
71. Profiling Hippocampal Neuronsafter Early Preconditioning with Certain 2014
Excitatory Amino Acids RevealsmGluR3 and mGluR7Contribute to
Neuronal Survival
L.K. Friedman and A.M. Slomko (USA)
72. Epigenetic down-regulation of type-2 metabotropic glutamate receptors
is linked to selective neuronal vulnerability following global transient brain
ischemia
M. Motolese, M. Cannella, F. Mastroiacovo, A. Gaglione, B. Riozzi, L. Di Menna, R.
Gradini, G. Battaglia,V. Bruno and F. Nicoletti (Italy and France)
73. mGlu4 receptor positive allosteric modulators exert different action at
corticostriatal vs. striatopallidal synapses: implications for Parkinson's
disease treatment
P. Gubellini, E. Dale, C. Melon, L. Kerkerian-Le Goff and D. Doller (France and
USA)
74. Novel Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric
Modulators For Multiple Sclerosis: in vitro and in vivo Pharmacological
Characterization
S. Célanire, C. Mordant, M. Heroux, I. Royer-Urios, C. Orabona, C. Volpi, G.
Mondanelli, M. T. Pallotta, F. Fallarino,L. Galibert, S. Poli and U. Grohmann
(Switzerland and Italy)
75.Effects of group III mGluRs modulation in the globuspallidus of
Parkinsonian rats
T. Deltheil, N. Turle-Lorenzo and M. Amalric (France)
76. Adaptive changes in the expression of Grm4 and Grm5 genes in the
mouse striatum of acute models of drug-induced parkinsonism
M. Cannella, M. Motolese, D. Bucci, G. Molinaro, A. Traficante, J. Marrocco, V.
Bruno, F. Nicoletti and G. Battaglia (Italy)
77. Imaging the antiparkinsonian effects of the novel Metabotropic Glutamate
Receptor subtype 4 positive allosteric modulator ADX88178
N. Byun, A. Huang, R. A. Baheza, R. L. Barry, C.W. Lindsley, C. Hopkins, C.
Niswender, C. K. Jones, J. C. Gore and P. J. Conn (USA)
78.The metabotropic glutamate receptor subtype 5 positive allosteric
modulator VU0360172modulates dopaminergiccircuits
N. Byun, A. Ghoshal, R.L. Barry, R.A. Baheza, W. Pham, J.C. Gore and P.J. Conn
(USA)
29
The following contributors are acknowledged
30
Taormina,
Sicily-Italy
September 28th
October 3rd,
2014
31
Presidenza della Regione Siciliana
Assessorato Regionale alla Sanità
Assessorato Regionale ai Beni Culturali ed Ambientali
e della Pubblica Istruzione
Comune di Taormina
Taormina Arte
Servizio Parco Archeologico di Naxos
e delle aree archeologiche di Giardini Naxos,
Taormina, Francavilla e dei Comuni limitrofi.
32

FINAL PROGRAM

OFFICIAL RESULTS

Mineralocorticoids:

CORRICAPODANNO 2015 Taormina

Document 5218871

Document 5219165